spot_img

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc....

MAIA Biotechnology Announces $736,600 Private Placement

CHICAGO, IL, Oct. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing...

Top Stories

admin

NABR Comment on IUCN Determination

WASHINGTON, Oct. 14, 2025 /PRNewswire/ -- The International Union for Conservation of Nature (IUCN) issued a decision on October 9, 2025, to retain the "Endangered" status determination for long-tailed macaque ("LTM") monkeys (Macaca fascicularis). The...
admin

Green Street Brings Its Industry-Leading Public Market Research and REIT Data...

SYDNEY, Oct. 14, 2025 /PRNewswire/ -- Green Street, the leading provider of trusted commercial real estate (CRE) and infrastructure intelligence, predictive analytics, and unbiased insights across North...

Most Popular

People

Soleil Belmont Park Unveils World-Class Resort Amenities in Canton, Georgia

admin
People

Single-Use Packaging Alternatives Market Players and Value Chain Analysis

admin
People

Wellness Beyond the Bowl

admin
People

LGI Homes Announces Rivenwick Village: A New Community Offering Townhome Living...

admin
People

Curves Ahead: Cardi B Partners with HSIA to Declare a New...

admin
admin

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to seven (7) new employees to purchase 161,600 ordinary...
admin

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Company determined to cancel its previously adjourned special...
spot_img

Category

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2...

admin

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry...

admin